The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.

ABSTRACT:

Introduction

Assessment of short-term intra- and inter-individual variability for Alzheimer's disease (AD) plasma biomarkers is essential for clinically relevant interpretation of biomarker levels. We hypothesized that the variability of plasma tau phosphorylated at threonine 217 (p-tau217) could be reduced by combining it with a tau marker, plasma brain-derived tau (BD-tau), as the p-tau217/BD-tau ratio.

Methods

Three consecutive blood samples were collected from memory clinic patients within 36 days. Patients were dichotomized by cerebrospinal fluid (CSF) amyloidosis (Aβ+ = 29, Aβ- = 18). We compared intra- and inter-individual variability (coefficient of variation [CV]) in the plasma p-tau217/BD-tau ratio with p-tau217 alone and tested if kidney function, glycated hemoglo

SUBMITTER: Clemmensen FK 

PROVIDER: S-EPMC12358005 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature